These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3413032)

  • 1. Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers.
    Bonde J; Jensen NM; Pedersen LE; Graudal NA; Angelo HR; Kampmann JP
    Pharmacol Toxicol; 1988 May; 62(5):298-301. PubMed ID: 3413032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition kinetics of disopyramide in human healthy volunteers described by an open three compartment model.
    Bonde J; Jensen NM; Pedersen LE; Angelo HR; Rasmussen SN; Trap-Jensen J; Kampmann JP
    Pharmacol Toxicol; 1989 May; 64(5):412-6. PubMed ID: 2771866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1988; 35(3):313-7. PubMed ID: 3181285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
    Lima JJ; Boudoulas H; Shields BJ
    Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of disopyramide in decreased hepatic function.
    Bonde J; Graudal NA; Pedersen LE; Balsløv S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1986; 31(1):73-7. PubMed ID: 3780831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
    Lima JJ; Haughey DB; Leier CV
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
    Hasselström J; Enquist M; Hermansson J; Dahlqvist R
    Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
    Cunningham JL; Shen DD; Shudo I; Azarnoff DL
    Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renal clearance of disopyramide after bolus intravenous injection.
    Lawrence JR; Bryson SM; Sumner DJ; Campbell BC; Whiting B
    Biopharm Drug Dispos; 1979; 1(2):51-7. PubMed ID: 552861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The mechanism of the renal excretion of disopyramide in rats. I].
    Ito T; Takahashi Y; Tomidokoro K; Nishino T; Fukuzawa Y; Chiba K; Miyazaki S; Takada M
    Yakugaku Zasshi; 1992 May; 112(5):336-42. PubMed ID: 1403666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ethanol intake on disopyramide elimination by healthy volunteers.
    Olsen H; Bredesen JE; Lunde PK
    Eur J Clin Pharmacol; 1983; 25(1):103-5. PubMed ID: 6617710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
    Giacomini KM; Blaschke TF
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():42-8. PubMed ID: 6705426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog.
    Blonde L; Wehmann RE; Steiner AL
    J Clin Invest; 1974 Jan; 53(1):163-72. PubMed ID: 4357610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of age and smoking on the elimination of disopyramide.
    Bonde J; Pedersen LE; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Br J Clin Pharmacol; 1985 Nov; 20(5):453-8. PubMed ID: 4074615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disopyramide concentrations in human plasma and saliva: comparison of disopyramide concentrations in saliva and plasma unbound concentrations.
    Sagawa K; Mohri K; Shimada S; Shimizu M; Muramatsu J
    Eur J Clin Pharmacol; 1997; 52(1):65-9. PubMed ID: 9143870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.